Question special

In primary care practice, we do not see GLP-1 agonists being commonly used for diabetes control for several reasons including cost and because it is administered by injection. Was adherence to liraglutide measured in some way during the trial? If so, how was it assessed? This would be interesting to know since if GLP-1 agonists are recommended for weight loss therapy in the future, patient adherence will be a big issue.